Garlic compound, diallyl disulfide induces cell cycle arrest in prostate cancer cell line PC-3

Arumugam Arunkumar1, Marati Radhakrishnan Vijayababu, Narasimman Srinivasan

  • 1Department of Endocrinology, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, 600 113, India.

Insights

Diallyl disulfide (DADS), a garlic compound, effectively inhibits prostate cancer cell growth and induces cell cycle arrest. This study demonstrates DADS

Area of Science:

  • Oncology
  • Molecular Biology
  • Natural Product Chemistry

Background:

  • Prostate cancer is a leading cause of cancer-related death in men, with limited therapeutic options for advanced stages.
  • Androgen-independent prostate cancer remains a significant clinical challenge.
  • Aged garlic extract has shown potential in suppressing cancer growth.

Purpose of the Study:

  • To investigate the antiproliferative effects of diallyl disulfide (DADS) on prostate cancer cells in vitro.
  • To determine if DADS can induce cell cycle arrest in prostate cancer cells.
  • To elucidate the molecular mechanisms underlying DADS' anti-cancer activity.

Main Methods:

  • Prostate cancer cell lines were treated with varying concentrations of DADS.
  • Cell proliferation was assessed using MTT assay.
  • Cell cycle arrest was analyzed by propidium iodide staining and flow cytometry.
  • Western blotting was employed to examine the expression of key cell cycle regulatory proteins, including cyclin A, cyclin B1, and CDK1.

Main Results:

  • DADS demonstrated a dose-dependent inhibition of prostate cancer cell growth.
  • DADS induced significant cell cycle arrest at the G2/M transition in PC-3 cells at concentrations of 25 microM and 40 microM.
  • Western blot analysis revealed that DADS downregulates the expression of CDK1, a critical regulator of the cell cycle.

Conclusions:

  • Diallyl disulfide (DADS) exhibits potent antiproliferative activity against prostate cancer cells.
  • DADS effectively induces cell cycle arrest at the G2/M phase, mediated by the downregulation of CDK1.
  • These findings suggest that DADS is a promising agent for the development of novel therapies for prostate cancer.